Overview

A Trial Comparing Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if treatment with Degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes, who are admitted to the hospital and then transition at home, after discharge from the hospital.

Phase:

Phase 4

Details

Lead Sponsor:

Emory University

Collaborator:

Novo Nordisk A/S

Treatments:

Hypoglycemic Agents
Insulin
Insulin Aspart
Insulin Glargine
Insulin, Globin Zinc
Insulin, Long-Acting